Latin American Next-Gen Sequencing Market Sees Multi-Faceted Development

Latin American Next-Gen Sequencing Market Sees Multi-Faceted Development

The government of Brazil was an early proponent of genome research and at one point had accomplished one-third of all human DNA sequencing. Originally led by a British geneticist who has since sought to spark similar research in other emerging regions (South Africa, China, Russia), Brazilian sequencing activities have proliferated along various lines of research and represent the core of regional Latin American demand for next-sequencing platforms. Kalorama Information recently profiled the Lati...

  • by bcarlson@marketresearch.com
  • April 24 2014


Novartis Benefits Most From Recent Deals With Glaxo, Lilly

Novartis Benefits Most From Recent Deals With Glaxo, Lilly

Novartis, Glaxo Smith Kline and Eli Lilly engaged in a series of transactions designed to play up each company’s strength. We think giant Novartis benefits a bit more from its recently announced transactions with Glaxo Smith Kline. The two drug makers will cooperate and among other transactions, Glaxo will buy Novartis’s vaccine business and Novartis will gain Glaxo’s oncology drug pipeline. Kalorama broke out revenues of major pharma companies by therapeutic area in its recent report Top 25 Pha...

  • by bcarlson@marketresearch.com
  • April 21 2014
  • China


Nearly 40 million Surgeries Performed in China Last Year

Nearly 40 million Surgeries Performed in China Last Year

Our newly -released Surgical Procedure Volumes: Global Analysis report informs us that the total number of surgical procedures in China is estimated at 39.5 million for 2013. This is nearly one sixth of the world’s surgical operations. The majority of procedures are in the area of obstetrical and gynecological procedures, followed by digestive and gastrointestinal system procedures.

China boasts 1.3 billion people and this is expected to grow to 1.4 by 2020. The growth of the Chinese economy, ...


Kalorama Consumer Survey - Retail Clinics Solidify Role in U.S. Healthcare

Kalorama Consumer Survey - Retail Clinics Solidify Role in U.S. Healthcare

According to a recent consumer survey conducted by Kalorama Information, U.S. retail clinics have delivered on their promise to carve out and elaborate on a specific role in health care. In the last two years, the share of respondents that have ever visited a retail clinic (located in a drug store, grocery store or retail supercenter) has increased from approximately one-fifth to over one-third. The rising utilization of retail clinics has occurred within a well-defined, yet diverse set of avail...


H.R. 4032 Unveils the Next Savings Tool for Part B Clinical Lab Testing

H.R. 4032 Unveils the Next Savings Tool for Part B Clinical Lab Testing

The Clinical Laboratory Fee Schedule (CLFS) has been a frequent target of federal cost saving initiatives in Medicare; recent hits to the schedule have included negative “productivity” adjustments offsetting inflation adjustments; ACA-initiated annual schedule cuts; and one-off cuts. Signed by President Obama at the beginning of this month, H.R. 4032 (“Protecting Access to Medicare Act of 2014”) sets the groundwork for a new system of cost-saving adjustments to the schedule ( Section 1834A ):

...


Pre-Packed: Roche Arrives in Molecular POC with IQuum Acquisition

Pre-Packed: Roche Arrives in Molecular POC with IQuum Acquisition

Count Roche among the IVD leaders zeroed in on molecular point-of-care (POC) diagnostics. The global IVD giant recently announced its acquisition of IQuum, a company that bolsters Roche’s “molecular diagnostics offerings…that serve the point of care segment.” The $450 million deal comes in the wake of similarly minded acquisitions of BioFire Diagnostics by bioMérieux (January 2014) and PathoGene by DxNA (January 2014). The true targets behind these acquisitions are hard to miss: over $20 billio...

  • by esalazar@marketresearch.com
  • April 7 2014
  • U.S. IVD


Targeting Growth in the U.S. IVD Market: Projected Test Segment Metrics through 2018

Targeting Growth in the U.S. IVD Market: Projected Test Segment Metrics through 2018

An IVD company looking to expand or establish its presence in the U.S. market is advised to pick its spots; many IVD segments are highly competitive or feature clear-cut market leaders. Yet in other segments, unmet clinical demand and responsive innovation will create billions of dollars in added market revenue over the next five years. Derived from market segmentation and projections in The U.S. Market for In Vitro Diagnostic Tests , Kalorama Information introduces the following relative market...

  • by bcarlson@marketresearch.com
  • April 4 2014


Quadrivalents Boost Flu Vaccine Sales

Quadrivalents Boost Flu Vaccine Sales

The 2013 influenza season was the first in which quadrivalent influenza vaccines with an extra B strain were available in the U.S. According to our upcoming vaccine market report, that is one of the factors, combined with a rougher-than-average season, that helped revenues for flu vaccine makers last year. We estimate that in 2013, influenza vaccines generated $3.1 billion in revenues. Until 2013, seasonal influenza vaccines included only one B strain. However, influenza B has been a common caus...


Stable Epidemiological Factors Ground U.S. Food Animal Diagnostics Market

Stable Epidemiological Factors Ground U.S. Food Animal Diagnostics Market

Recent market entrants and product introductions to U.S. veterinary diagnostics have predominated in the companion animal or pet segment. Since 2012, new market players for animal disease test kits in the United States - Biogal/Galed Laboratories, Princeton BioMeditech, and InBios - have launched approved tests for canine distemper, canine heartworm, and West Nile virus. Overall, nearly half of the infectious disease tests introduced between 2012 and 2014 in the United States were for companion ...